OA10109A - Pharmaceutical composition of 5ht1-like receptor agonists for rectal administration - Google Patents

Pharmaceutical composition of 5ht1-like receptor agonists for rectal administration Download PDF

Info

Publication number: OA10109A
Authority: OA; OAPI
Prior art keywords: pharmaceutical composition; daims; methyl; pharmaceutically acceptable; active ingrédient
Prior art date: 1992-05-07

Application number

OA60578A

Other languages

English (en)

Inventor

Nadine Merlet

Isabelle Richard

Isabelle Thielemans

Original Assignee

Glaxo Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-07

Filing date

1994-11-04

Publication date

1996-12-18

1994-11-04 Application filed by Glaxo Lab Sa filed Critical Glaxo Lab Sa

1996-12-18 Publication of OA10109A publication Critical patent/OA10109A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
239000000018 receptor agonist Substances 0.000 title claims abstract description 8
229940044601 receptor agonist Drugs 0.000 title claims abstract description 8
239000000203 mixture Substances 0.000 claims abstract description 26
150000001875 compounds Chemical class 0.000 claims abstract description 15
239000012458 free base Substances 0.000 claims abstract description 9
239000003937 drug carrier Substances 0.000 claims abstract description 5
238000000034 method Methods 0.000 claims abstract description 5
208000002193 Pain Diseases 0.000 claims abstract description 4
238000004519 manufacturing process Methods 0.000 claims abstract 2
239000000829 suppository Substances 0.000 claims description 10
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical group CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 9
208000019695 Migraine disease Diseases 0.000 claims description 7
206010027599 migraine Diseases 0.000 claims description 7
239000002585 base Substances 0.000 claims description 6
206010019233 Headaches Diseases 0.000 claims description 4
231100000869 headache Toxicity 0.000 claims description 4
208000006561 Cluster Headache Diseases 0.000 claims description 3
208000018912 cluster headache syndrome Diseases 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
206010043269 Tension headache Diseases 0.000 claims description 2
208000008548 Tension-Type Headache Diseases 0.000 claims description 2
208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 4
241000124008 Mammalia Species 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
229940116364 hard fat Drugs 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
239000004480 active ingredient Substances 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
239000003814 drug Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 4
239000007909 solid dosage form Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 3
239000003925 fat Substances 0.000 description 3
210000003752 saphenous vein Anatomy 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
241001514645 Agonis Species 0.000 description 1
241000792859 Enema Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
240000006474 Theobroma bicolor Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000007705 chemical test Methods 0.000 description 1
230000001595 contractor effect Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
AMKVXSZCKVJAGH-UHFFFAOYSA-N naratriptan Chemical compound C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AMKVXSZCKVJAGH-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000003027 oil sand Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000007892 solid unit dosage form Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

OA60578A 1992-05-07 1994-11-04 Pharmaceutical composition of 5ht1-like receptor agonists for rectal administration OA10109A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB929209882A GB9209882D0 (en)	1992-05-07	1992-05-07	Compositions

Publications (1)

Publication Number	Publication Date
OA10109A true OA10109A (en)	1996-12-18

Family

ID=10715158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60578A OA10109A (en)	1992-05-07	1994-11-04	Pharmaceutical composition of 5ht1-like receptor agonists for rectal administration

Country Status (33)

Country	Link
US (1)	US5705506A (2)
EP (1)	EP0639072B1 (2)
JP (1)	JPH07506570A (2)
KR (1)	KR100253111B1 (2)
AT (1)	ATE163850T1 (2)
AU (1)	AU670083B2 (2)
BE (1)	BE1007024A5 (2)
BG (1)	BG62120B1 (2)
BR (1)	BR1100108A (2)
CA (1)	CA2135179C (2)
CH (1)	CH685920A5 (2)
CY (1)	CY2039B1 (2)
CZ (1)	CZ283512B6 (2)
DE (1)	DE69317418T2 (2)
ES (1)	ES2113533T3 (2)
FR (1)	FR2690847B1 (2)
GB (2)	GB9209882D0 (2)
GR (1)	GR3026584T3 (2)
HK (1)	HK95697A (2)
HU (2)	HU227338B1 (2)
IE (1)	IE75203B1 (2)
IL (1)	IL105468A (2)
IT (1)	IT1261471B (2)
NO (1)	NO306700B1 (2)
NZ (1)	NZ252132A (2)
OA (1)	OA10109A (2)
RO (1)	RO112993B1 (2)
RU (1)	RU2118527C1 (2)
SG (1)	SG46649A1 (2)
TW (1)	TW231970B (2)
UA (1)	UA37206C2 (2)
WO (1)	WO1993021916A1 (2)
ZA (1)	ZA933178B (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2434297A (en) *	1996-05-23	1997-12-09	Alcon Laboratories, Inc.	The use of 5-ht1b/1d agonists to treat ocular pain
US7189753B1 (en)	1997-11-06	2007-03-13	Cady Roger K	Preemptive prophylaxis of migraine
DK1064942T3 (da) *	1998-03-26	2004-11-01	Fujisawa Pharmaceutical Co	Sustained release-fremstilling af et makrolid
AU3731400A (en) *	1999-03-05	2000-09-21	Trustees Of University Technology Corporation, The	Methods and compositions useful in inhibiting apoptosis
AR056690A1 (es) *	2005-10-14	2007-10-17	Athersys Inc	Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
EP2124556B1 (en)	2006-10-09	2014-09-03	Charleston Laboratories, Inc.	Pharmaceutical compositions
ES2620672T3 (es)	2008-01-09	2017-06-29	Charleston Laboratories, Inc.	Comprimidos de doble capa que comprenden oxicodona y prometazina
WO2011006012A1 (en)	2009-07-08	2011-01-13	Charleston Laboratories Inc.	Pharmaceutical compositions
RU2611376C2 (ru)	2010-10-15	2017-02-21	Контера Фарма Апс	Фармацевтическая композиция для лечения, профилактики или облегчения двигательных расстройств и ее применение
NZ700474A (en)	2012-04-18	2016-10-28	Contera Pharma Aps	Orally available pharmaceutical formulation suitable for improved management of movement disorders
JP2019507181A (ja)	2016-03-04	2019-03-14	チャールストンラボラトリーズ，インコーポレイテッド	医薬組成物
AU2017297718B2 (en)	2016-07-11	2023-06-08	Contera Pharma A/S	Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZW19381A1 (en) *	1980-08-12	1983-03-09	Glaxo Group Ltd	Heterocyclic compounds
GB2082175B (en) *	1980-08-12	1984-05-02	Glaxo Group Ltd	Heterocyclic compounds
NL8103764A (nl) *	1980-08-12	1982-03-01	Glaxo Group Ltd	Heterocyclische verbindingen, werkwijze ter bereiding daarvan, alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten.
IT1170387B (it) *	1982-06-07	1987-06-03	Glaxo Group Ltd	Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
HU196752B (en) *	1983-12-06	1989-01-30	Glaxo Group Ltd	Process for production of medical compositions containing indole-derivatives and these compounds
GB8419575D0 (en) *	1984-08-01	1984-09-05	Glaxo Group Ltd	Chemical compounds
GB2162522B (en) *	1984-08-01	1988-02-24	Glaxo Group Ltd	An indole derivative
IT1181741B (it) *	1984-12-04	1987-09-30	Glaxo Group Ltd	Derivati di indolo,procedimento per prepararli e composizioni farmaceutiche che li contengono
GB8431426D0 (en) *	1984-12-13	1985-01-23	Glaxo Group Ltd	Chemical compounds
EP0225726B1 (en) *	1985-11-08	1991-04-17	Glaxo Group Limited	Indole derivatives
EP0303507B1 (en) *	1987-08-13	1993-07-28	Glaxo Group Limited	Indole derivatives
PT97888B (pt) *	1990-06-07	1998-12-31	Zeneca Ltd	Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem

1992
- 1992-05-07 GB GB929209882A patent/GB9209882D0/en active Pending
1993
- 1993-04-20 IL IL10546893A patent/IL105468A/en not_active IP Right Cessation
- 1993-05-03 US US08/331,485 patent/US5705506A/en not_active Expired - Fee Related
- 1993-05-03 EP EP93909884A patent/EP0639072B1/en not_active Expired - Lifetime
- 1993-05-03 AU AU40640/93A patent/AU670083B2/en not_active Ceased
- 1993-05-03 ES ES93909884T patent/ES2113533T3/es not_active Expired - Lifetime
- 1993-05-03 HU HU9403188A patent/HU227338B1/hu unknown
- 1993-05-03 RO RO94-01790A patent/RO112993B1/ro unknown
- 1993-05-03 AT AT93909884T patent/ATE163850T1/de active
- 1993-05-03 DE DE69317418T patent/DE69317418T2/de not_active Expired - Lifetime
- 1993-05-03 CA CA002135179A patent/CA2135179C/en not_active Expired - Fee Related
- 1993-05-03 WO PCT/EP1993/001077 patent/WO1993021916A1/en not_active Ceased
- 1993-05-03 CZ CZ942723A patent/CZ283512B6/cs not_active IP Right Cessation
- 1993-05-03 RU RU94046069/14A patent/RU2118527C1/ru not_active IP Right Cessation
- 1993-05-03 NZ NZ252132A patent/NZ252132A/en not_active IP Right Cessation
- 1993-05-03 UA UA94115989A patent/UA37206C2/uk unknown
- 1993-05-03 JP JP5518928A patent/JPH07506570A/ja active Pending
- 1993-05-05 SG SG1996007136A patent/SG46649A1/en unknown
- 1993-05-05 GB GB9309209A patent/GB2266665B/en not_active Expired - Lifetime
- 1993-05-06 BE BE9300467A patent/BE1007024A5/fr not_active IP Right Cessation
- 1993-05-06 ZA ZA933178A patent/ZA933178B/xx unknown
- 1993-05-06 CH CH139793A patent/CH685920A5/fr not_active IP Right Cessation
- 1993-05-06 IE IE930339A patent/IE75203B1/en not_active IP Right Cessation
- 1993-05-06 IT ITRM930286A patent/IT1261471B/it active IP Right Grant
- 1993-05-06 FR FR9305432A patent/FR2690847B1/fr not_active Expired - Lifetime
- 1993-05-12 TW TW082103742A patent/TW231970B/zh active
1994
- 1994-11-04 OA OA60578A patent/OA10109A/en unknown
- 1994-11-04 NO NO944214A patent/NO306700B1/no not_active IP Right Cessation
- 1994-11-05 KR KR1019940703950A patent/KR100253111B1/ko not_active Expired - Fee Related
- 1994-11-07 BG BG99167A patent/BG62120B1/bg unknown
1995
- 1995-06-29 HU HU95P/P00531P patent/HU211638A9/hu unknown
1996
- 1996-12-24 BR BR1100108-9A patent/BR1100108A/pt active IP Right Grant
1997
- 1997-06-26 HK HK95697A patent/HK95697A/xx not_active IP Right Cessation
1998
- 1998-04-10 GR GR980400773T patent/GR3026584T3/el unknown
- 1998-04-30 CY CY9802039A patent/CY2039B1/xx unknown

Also Published As

Publication number	Publication date
CA2135179C (en)	2000-12-05
IL105468A0 (en)	1993-08-18
HUT71418A (en)	1995-11-28
ITRM930286A0 (it)	1993-05-06
ES2113533T3 (es)	1998-05-01
FR2690847B1 (fr)	1995-06-09
HU227338B1 (en)	2011-04-28
IL105468A (en)	1998-09-24
DE69317418D1 (de)	1998-04-16
EP0639072B1 (en)	1998-03-11
GB2266665A (en)	1993-11-10
BR1100108A (pt)	1999-12-07
GB9209882D0 (en)	1992-06-24
CZ272394A3 (en)	1995-10-18
RO112993B1 (ro)	1998-03-30
NO944214L (no)	1994-11-07
BG62120B1 (bg)	1999-03-31
HU211638A9 (en)	1995-12-28
GR3026584T3 (en)	1998-07-31
FR2690847A1 (fr)	1993-11-12
ATE163850T1 (de)	1998-03-15
HK95697A (en)	1997-08-08
JPH07506570A (ja)	1995-07-20
AU4064093A (en)	1993-11-29
CY2039B1 (en)	1998-04-30
IE930339A1 (en)	1993-11-17
IT1261471B (it)	1996-05-23
IE75203B1 (en)	1997-08-27
WO1993021916A1 (en)	1993-11-11
AU670083B2 (en)	1996-07-04
EP0639072A1 (en)	1995-02-22
ZA933178B (en)	1994-01-10
US5705506A (en)	1998-01-06
NZ252132A (en)	1996-09-25
GB9309209D0 (en)	1993-06-16
GB2266665B (en)	1996-05-22
CZ283512B6 (cs)	1998-04-15
CA2135179A1 (en)	1993-11-11
BG99167A (bg)	1995-06-30
ITRM930286A1 (it)	1994-11-06
RU2118527C1 (ru)	1998-09-10
CH685920A5 (fr)	1995-11-15
KR100253111B1 (en)	2000-07-01
DE69317418T2 (de)	1998-07-30
TW231970B (2)	1994-10-11
BE1007024A5 (fr)	1995-02-21
NO944214D0 (no)	1994-11-04
UA37206C2 (uk)	2001-05-15
SG46649A1 (en)	1998-02-20
NO306700B1 (no)	1999-12-13

Publication	Publication Date	Title
OA10109A (en)	1996-12-18	Pharmaceutical composition of 5ht1-like receptor agonists for rectal administration
RU2146140C1 (ru)	2000-03-10	Средство для лечения нарушений сна и фармацевтическая композиция на его основе
CZ288834B6 (cs)	2001-09-12	Farmaceutický prostředek k ošetřování desynchronizačních poruch
IL155322A (en)	2012-12-31	Compositions of vehicles containing modafinil
AP544A (en)	1996-10-11	Compositions for rectal administration
EP0671908B1 (en)	1998-05-06	Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers
JPH11507671A (ja)	1999-07-06	良性前立腺過形成を処置するためのメラトニンアゴニスト
AU3810100A (en)	2000-10-04	Stable pharmaceutical application form for paroxetin anhydrate